Navigation Links
Research sheds new light on mechanisms of T-ALL, a form of leukemia that primarily affects children
Date:12/23/2012

Acute lymphatic leukemia (ALL) is the most common cancer in children under the age of 14 years. With optimum treatment, approximately 75 % of children are currently cured, but the treatment consists of severe chemotherapy with many side effects. In collaboration with international research teams, scientists at VIB, KU Leuven and UZ Leuven have identified new genetic mutations that lead to T-ALL, a variant of ALL. They have unmasked the ribosome the molecular machine in the cell that is involved in the production of proteins as a weak spot in leukemia cells. Their research has also shown that there is a difference in T-ALL between adults and children. Both findings can be important in the search for improved treatments for T-ALL.

Jan Cools (VIB/KU Leuven):"We have discovered that there is a clear genetic difference between T-ALL in children and in adults. This could be an explanation why adults do not respond as well to the current therapy."

Stein Aerts (KU Leuven):"This is a beautiful example of the power of genome sequencing in cancer research. New technologies and large-scale bio-informatics allow us to study a lot of data simultaneously. This allows us to discover links that would have been impossible to find in the past."

T-cell acute lymphatic leukemia (T-ALL)

The formation of white blood cells is disrupted by leukemia. The cells in the bone marrow that should mature into white blood cells multiply unchecked without maturing completely. These immature blood cells compromise the production of normal blood cells. This makes patients more susceptible to infections. Leukemia occurs in different forms; in the case of T-ALL, there is an accumulation of immature white blood cells over a very short period of time. With optimum treatment involving chemotherapy approximately 75 % of children are currently cured. For adults, the chance of a cure is below 50 %. Chemotherapy is associated with many side effects. The search for a more specific treatment can only start once we know what causes T-ALL.

7 new genes with a key role in T-ALL identified

T-ALL only occurs if errors in various genes occur simultaneously. It is important to determine which genes play a key role. Kim De Keersmaecker, Zeynep Kalender Atak, Jan Cools and Stein Aerts have identified a series of defects in 15 important genes, of which 7 have not previously been associated with T-ALL. They used next-generation sequencing to analyze the 20,000+ genes of 67 T-ALL patients. This technique allows for very fast analysis and comparison of the complete DNA sequence of healthy and sick individuals.

A difference between adults and children

The investigators from Leuven also discovered a difference between T-ALL in children and in adults. T-ALL in adults contains significantly more mutations than in children. The leukemia cells in adults also contain mutations in other genes than in children. This genetic difference could be a possible explanation why adults do not respond as well to the current therapy.

A weak point in leukemia cells exposRPL5 and RPL10 two newly identified genes form A weak point in leukemia cells exposed

RPL5 and RPL10 two newly identified genes form part of the ribosome: this is the complex in the cell that produces proteins. The scientists hereby demonstrated for the first time that defects in the ribosome can also play a role in cancer activation. Experiments in yeast cells confirm that mutations in RPL10 cause a change in the ribosome.

Kim De Keersmaecker (VIB/KU Leuven):"This could be a weak point of the leukemia cells: all cells need properly functioning ribosomes to survive and to grow. These 'defective' ribosomes in the leukemia cells could be a new suitable target for the development of targeted therapies."


'/>"/>

Contact: Kris Van der Beken
kris.vanderbeken@vib.be
32-473-783-435
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related medicine news :

1. Grape News: Global Wine Manufacturing Industry Market Research Report from IBISWorld has Been Updated
2. UNC researcher receives AACR and Kure It Kidney Cancer research grant
3. New Research Survey Indicates That Natural Family Planning Method CycleBeads® Helps Women Planning Pregnancies
4. AACR and Kure It announce 2 Kidney Cancer Research grant recipients
5. U of T Researchers uncover major source of evolutionary differences among species
6. UGA research offers new targets for stroke treatments
7. Temple researcher shows diabetes, blood pressure link to colon cancer recurrence, survival
8. Radiation Research Society honors 2 faculty
9. Hangover Research Institute Launched By Hangover Heaven Doctor
10. MRIs reveal signs of brain injuries not seen in CT scans, UCSF/SFGH researchers report
11. Researchers find model system to study promising cancer drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... 2016 , , , WHEN: ... 2016 , , , , LOCATION: , , , Online, ... , , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global ... Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager ... pharmaceutical industry is witnessing an exceptional era. Several new demand spaces, ...
(Date:6/23/2016)... , June 23, 2016 The vast ... an outpatient dialysis facility.  Treatments are usually 3 times ... hours per visit, including travel time, equipment preparation and ... patient, but especially grueling for patients who are elderly ... a skilled nursing and rehabilitation centers for some duration ...
Breaking Medicine Technology: